281 Albany Street281 Albany Street, Cambridge, MA
Themes: Innovation and collaboration
Renovation and renewal
The rejuvenated laboratory building at 281 Albany Street is now home to Aileron Therapeutics, a dynamic new company creating novel biopharmaceuticals to aid in the fight against disease.
Themes and priorities
In 2010, MIT transformed a 32,000 square foot property at 281 Albany Street from an obsolete manufacturing plant into a next-generation laboratory facility. In keeping with its history of encouraging collaboration and innovation, the Institute has leased the entire laboratory and office space to Aileron Therapeutics, Inc., a biopharmaceutical company founded in 2005 to develop and advance a revolutionary class of drugs. These drugs, called Stapled Peptides, have demonstrated a unique ability to penetrate cells throughout the body and modulate cell interactions relating to disease. Aileron is building a pipeline of promising new drug candidates, currently targeting cancer, infectious disease, metabolic disease, and immune/inflammatory diseases.
In addition to renovating and upgrading the building’s interior facilities, MIT added windows around the perimeter, relocated the loading dock, and constructed a new accessible entrance. The overall transformation has improved the streetscape along Albany Street and contributed to the area’s appeal for both pedestrians and future research partners.